Streptomyces are a genus of Actinobacteria capable of producing structurally diverse natural products. Here we report the isolation and characterization of a biosynthetically talented Streptomyces (Streptomyces sp. SD85) from tropical mangrove sediments. Whole-genome sequencing revealed that Streptomyces sp. SD85 harbors at least 52 biosynthetic gene clusters (BGCs), which constitute 21.2% of the 8.6-Mb genome. When cultivated under lab conditions, Streptomyces sp. SD85 produces sceliphrolactam, a 26-membered polyene macrolactam with unknown biosynthetic origin. Genome mining yielded a putative sceliphrolactam BGC (sce) that encodes a type I modular polyketide synthase (PKS) system, several β-amino acid starter biosynthetic enzymes, transporters, and transcriptional regulators. Using the CRISPR/Cas9-based gene knockout method, we demonstrated that the sce BGC is essential for sceliphrolactam biosynthesis. Unexpectedly, the PKS system encoded by sce is short of one module required for assembling the 26-membered macrolactam skeleton according to the collinearity rule. With experimental data disfavoring the involvement of a trans-PKS module, the biosynthesis of sceliphrolactam seems to be best rationalized by invoking a mechanism whereby the PKS system employs an iterative module to catalyze two successive chain extensions with different outcomes. The potential violation of the collinearity rule makes the mechanism distinct from those of other polyene macrolactams.
L-glutamate-derived starter unit and malonyl-CoA or methylmalonyl-CoA extender units. The PKS product undergoes cyclization and tailoring to yield the final macrolactam. The so-called collinearity rule 12, 13 for polyketide biosynthesis is strictly followed in the reported biosynthetic mechanisms. Structural diversity in the polyene macrolactams is generated via the utilization of different starter units (i.e. 3-meAsp or 3-aminobutyrate), varying composition of PKS modules and different tailoring enzymes.
Here we report a biosynthetically talented Streptomyces strain (Streptomyces sp. SD85) isolated from the sediment sample collected from a coastal mangrove forest of Singapore. Among the secondary metabolites produced by Streptomyces sp. SD85, we isolated and identified sceliphrolactam, a polyene macrolactam that shares structural similarity and potentially similar biosynthetic mechanism with vicenistatin and some other known macrolactams. Genome sequencing and gene inactivation experiments allowed us to identify the putative sceliphrolactam BGC to reveal the enzymes involved in the synthesis of the macrolactam scaffold and starter moiety, and a potentially iterative mechanism in the biosynthesis of the macrolactam polyene scaffold.
Results and Discussion
Streptomyces sp. SD85 produces sceliphrolactam and other secondary metabolites under lab cultivation conditions. Streptomyces sp. SD85 is one of the Actinobacteria strains that we isolated from sediment samples collected from the mangrove forest of Sungei Buloh Wetland Reserve, Singapore. After the cultivation in GYM Streptomyces medium, the secondary metabolites produced by Streptomyces sp. SD85 were extracted from the culture broth and mycelium using ethyl acetate and methanol respectively. The secondary metabolites were subsequently profiled using liquid chromatography couple with high-resolution mass spectrometry (LC-HRMS). Aided by an in-house natural product library, we identified several known compounds that include streptorubin B (a  member of ). The red pigment streptorubin B is produced in abundance and accounts for the red/orange appearance of the colonies (Fig. S1 ). In addition, Streptomyces sp. SD85 produces several potentially new compounds whose spectral signatures were not found in the database. The structure for one of the "unknown" compounds was established using HRMS and NMR spectroscopy (Figs S4-S10, Table S1 ). This compound, which was isolated from the mycelium, turned out to be sceliphrolactam (m/z = 482.2532
, which is a 3-amino-2-methylpropionate-containing polyene macrolactam that was isolated recently from a wasp-associated Streptomyces strain 11 .
Complete genome sequencing suggests that Streptomyces sp. SD85 is a biosynthetically talented strain. The biosynthetic pathway for sceliphrolactam has not been elucidated as of today. To identify the sceliphrolactam BGC and to further assess the biosynthetic potential of Streptomyces sp. SD85, we first obtained a draft genome using Illumina sequencing technology. Considering that the short reads from Illumina sequencing may cause mis-assembly, we re-sequenced the genome for the second time using the single molecule real time sequencing (SMRT ® ) technology (PacBio) to obtain the complete genome. The complete genome, which is highly similar to the draft genome except for the gap regions, revealed that the chromosome consists of 8,625,724 base pairs with an average GC content of 72.3%. Phylogenetic analysis based on 16 S rDNA sequences suggests S. hiroshimensis NBRC 3839(T) as the closest relative with a shared nucleotide identity of 99.52%. AntiSMASH 14 analysis using AntiSMASH 3.0 suggested that the genome contains at least 52 BGCs for the biosynthesis of different classes of secondary metabolites. The 52 BGCs occupy a total of 1.82 Mb and constitute 21.2% of the genome, which is higher than the 10.8% and 16.6% occupancy for S. coelicolor and S. avermitilis 15, 16 . Similar to the S. coelicolor and some other Streptomyces strains, most of the BGCs reside in the two subtelomeric regions of the genome ( Fig. 2A) . More than half of the BGCs are predicted to produce polyketide and ribosome or non-ribosome peptide-derived secondary metabolites (Table 1) . Seventeen BGCs have genes that encode type I, II or III PKS systems, including three type I modular PKS systems. Ten BGCs possess genes predicted to produce lantipeptide, thiopeptide or lasso-peptides; and eleven BGCs contain non-ribosomal peptide synthetase (NRPS) proteins. A few terpene BGCs were identified as evidenced by the presence of terpene synthase genes. Several BGCs are considered to be hybrid BGCs containing genes that code for more than one type of scaffold-synthesizing enzymes ( Table 1 ). Considering that fewer than ten secondary metabolites were detected in our LC/MS-based metabolite profiling, some of the BGCs could be suppressed due to transcriptional or translational regulation.
For PKS and NRPS proteins to be enzymatically active, the carrier protein domains of the PKS and NRPS proteins must undergo phosphopantetheinylation, a post-translational modification catalyzed by Sfp or AcpS-type 4'-phosphopantetheinyl transferases (PPTase) 17, 18 . The Streptomyces sp. SD85 genome harbors at least three genes encoding Sfp-type PPTases and one gene-encoding AcpS-type PPTase. All four PPTases are predicted to be discrete proteins with none of them integrated into the PKS or NRPS proteins as observed for some PKSs 19 .
Identification of sceliphrolactam BGC by gene inactivation.
With the complete genome in hand, the sceliphrolactam-producing Streptomyces sp. SD85 strain provides us with an opportunity to identify the sceliphrolactam BGC and decipher the biosynthetic pathway. As the macrolactam skeleton of sceliphrolactam is most likely generated by a type I modular PKS system, we first searched BGCs that contained type I modular pks genes. The genome of Streptomyces sp. SD85 harbors several BGCs that are predicted to contain type I pks or fas (fatty acid synthase) genes, but only three (BGC6, 11 and 37 (Table 1)) encode type I modular PKS systems. Based on the high similarity shared with the BGCs from the MIBiG database 14 , BGC6 and BGC37 are predicted to produce filipins and kirromycin respectively (Fig. 2B ) [20] [21] [22] . Assignment of the two BGCs is consistent with the detection of filipin III and factumycin (a close structural analogue of kirromycin) 23 in the culture broth. BGC11 encodes six Table 2 PKS proteins and a dozen of other enzymes, transporters and regulatory proteins (Fig. 2C ). Three uncharacterized BGCs that share high similarity with BGC11 were also found in the genomes of Streptomyces sp. SirexAA-E, Streptomyces sp. PAMC26508 and S. flavogriseus ATCC3331 (Fig. 2D ).
To find out whether BGC11 is responsible for sceliphrolactam biosynthesis, we used a CRISPR/Cas9 strategy to delete an internal fragment of the sceN gene, which encodes the first of the six PKS modules. The pCRISPR-Cas9 plasmid was employed to express Cas9, sgRNA and a DNA template required for homology directed repair (HDR) 24 . After cloning the sgRNA and homologous DNA sequences into the pCRISPR-Cas9 plasmid, we transformed Streptomyces sp. SD85 with the modified plasmid by the E. coli -Streptomyces conjugation method 24 . After Cas9-mediated DNA cleavage and repair, DNA gel analysis and DNA sequencing confirmed that a portion of sceN was successfully deleted (Fig. 3A,B) . It should be noted that we used five sgRNAs to target different protospacer adjacent motif (PAM) sites within the sceN gene and only one of the sgRNAs (sgRNA2) led to DNA cleavage and repair (Fig. 3B ). As already documented by other researchers, the efficiency of Cas9/sgRNA-mediated gene deletion in bacteria can vary greatly 25 . Subsequent metabolite analysis by HPLC confirmed the absence of sceliphrolactam in the culture broth of the ∆sceN mutant strain (Fig. 3C ). The gene inactivation experiment supports that the sce BGC encodes the enzymes and other proteins required for sceliphrolactam biosynthesis. This conclusion is further reinforced by the sequence similarity shared by the biosynthetic genes between sce and the vicenistatin BGC as discussed below.
Annotation of non-PKS biosynthetic genes in the sce gene cluster. In addition to the five PKS-encoding genes, the sce BGC also contains other genes predicted to code for non-PKS enzymes, membrane-embedded ABC transporters and two LuxR-type transcriptional regulators. The predicted functions of the biosynthetic enzymes, transporters and regulatory proteins are summarized in Table 1 . Here we describe that the annotation of the sce genes provides further support for the involvement of the sce BGC in sceliphrolactam biosynthesis.
The sce gene cluster has several genes (sceG-N) that share homology with a set of genes found in S. halstedii HC-34 for vicenistatin biosynthesis ( sceliphrolactam also contains a 3-amino-2-methylpropionate moiety. Considering the high sequence homology shared by the two sets of genes, the 3-amino-2-methylpropionate moiety of sceliphrolactam is likely to be synthesized by a similar pathway. Based on the function of starter-synthesizing enzymes in vicenistatin biosynthesis 27 , SceL and SceM, which are the homologs of VinH (Identity/Similarity: 57%/74%) and VinI (Identity/ Similarity: 62%/70%), are likely to form a coenzyme B 12 -dependent glutamate mutase that catalyzes the transmutation of glutamate (Fig. 4B) . SceI, a homolog of VinN (Identity/Similarity: 61%/75%), is predicted to transfer 3-methylaspartate onto the carrier protein SceH (homolog of VinL: Identity/Similarity: 64%/75%). SceK is the homolog of VinO (Identity/Similarity: 67%/79%) and is likely to catalyze the decarboxylation and epimerization of SceH-tethered 3-methylaspartate to 3-amino-2-methyl propionate; whereas SceJ (VinM homolog, Identity/Similarity: 58%/67%) is likely to catalyze the formation of an amide to protect the reactive amino group. SceG shares high sequence homology with the aminoacyltransferase VinK (Identity/Similarity: 69%/86%), with all the catalytic residues of VinK conserved 28 . Accordingly, SceG is likely responsible for transferring the 3-amino-2-methylpropionate group from SceH onto the ACP of the loading module of SceN 26, 29 . Apart from the starter biosynthetic genes, sceF encodes a protein (SceF) that shares high similarity with VinJ (Identity/Similarity: 71%/84%), an amidohydrolase or peptidase in vicenistatin biosynthesis 26, 30 . VinJ, which is distinct from other more common serine peptidases adopting an α/β hydrolase fold, plays a role by catalyzing the amide hydrolysis to generate the free amino group, which must be protected during the polyketide chain extension to prevent premature cyclization of intermediates 29 . Hence, the protection de-protection strategy for the reactive aminoacyl-ACP intermediates found in the biosynthesis of vicenistatin, amino marginolactone 31 and other natural products is most likely to be shared by sceliphrolactam biosynthesis. In addition, the presence of two cytochrome P450 genes (sceD & secE) in the BGC is also consistent with the two hydroxylated carbon atoms (C-10 and C-12) in sceliphrolactam (Fig. 4B) . The genes sceA and sceB encode a pair of thioredoxin and ferredoxin, which are likely to be the electron transfer proteins that supply electrons to the cytochrome P450 hydroxylases. (Fig. S10) . The stereochemistry of C-11 was assigned based on the observation that the KR 6 domain is a B-type KR domain [49] [50] [51] . Analysis of the Sce type I modular PKS. We performed detailed sequence analysis on the acyltransferase (AT), ketosynthase (KS), ketoreductase (KR) and dehydratase (DH) domains of all ten PKS modules encoded by the sce gene cluster. All AT, KS, KR and DH domains contain the essential catalytic residues and are predicted to be catalytically active. The substrate preference of AT domains of type-I PKS towards malonyl-CoA or methylmalonyl-CoA is defined by several key residues in the substrate binding pocket [32] [33] [34] . Sequence comparison suggests that the two AT domains from module-3 and module-8 are likely to use methylmalonyl-CoA as substrate. This is in accordance with the two methyl groups (C-26, C-27) in sceliphrolactam (Fig. 4B) . Meanwhile, protein sequence analysis suggests that the KR domains belong to the "B-type" KR that contains a conserved (L/V)D(D/N) motif, which is crucial for guiding polyketide intermediates into the active site of KR domains to produce "R"-configured β-hydroxyl groups (Fig. S2) .
To assemble the macrolactam skeleton of sceliphrolactam, the modular PKS system is expected to have eleven modules to join the 3-amino-2-methylpropionate starter unit with nine acetyl and two propionyl extender units. Surprisingly, the sce BGC only encodes ten PKS modules found in SceN, SceO, SceQ, SceR and SceS. According to the collinearity rule for PKS 12, 13 , the order of PKS modules in the biosynthetic complex should be reflected in the chromosomal order of the pks genes. Considering the collinearity rule is strictly followed in the biosynthesis of other known macrolactam polyenes, the Sce PKS system could represent a deviation from the orthodox systems and may feature an iterative module (Fig. 4C,D) we will discuss further below. To confirm that the shortage of a module is not because of erroneous assembly of the genome sequence, DNA segments at the boundaries of sceO, sceQ, sceR and sceS genes were amplified by PCR (Fig. S3) . The result confirms that the four genes form a continuous DNA fragment, and thus, rules out the existence of a gene encoding a "missing" module. Meanwhile, we did not detect other macrolactams in the biomass or culture broth of Streptomyces sp. SD85, which makes it tenuous to argue that sceliphrolactam is a minor product generated by the aberrant stuttering of a PKS module.
Evidence disfavoring the involvement of a trans-PKS module in sceliphrolactam biosynthesis.
There is a plausible explanation for the shortage of a PKS module in the Sce system without invoking the breakdown of the collinearity rule. This would involve the use of a trans-PKS module encoded by another gene located somewhere else in the genome. This trans-PKS module must be integrated into the mega-PKS protein complex by docking specifically between SceQ and SceR. Considering that the β-keto group remains unreduced for the chain extension catalyzed by the mysterious module, a potential trans-PKS module is most likely to have a KS-AT-ACP domain composition and contain docking domains that are compatible with the docking domains of SceR and SceQ. However, an inspection of the complete genome of Streptomyces sp. SD85 revealed that all the pks genes in the genome are accounted for by the 52 BGCs. We could not find any orphan PKS module with docking domains, let alone an orphan module with the KS-AT-ACP domain organization. We also searched the genome of the three Streptomyces strains that contain the homologous sce BGCs (Fig. 2C ) and did not find such orphan PKS module. Moreover, we identified the N-and C-terminal portions of SceN, SceO, SceQ, SceR and SceS that are predicted to fold into docking domains crucial for holding the PKS complex together (Fig. S13 ) 35 . The lack of a gene that encodes a potential trans-PKS module and the presence of compatible docking domains for SceR and SceQ seem to argue against the participation of a trans-PKS module.
To seek experimental evidence for or against the involvement of a trans PKS module, we constructed a mutant strain by fusing the sceQ and sceR genes on the chromosome. The rationale behind the experiment is that when the sceQ and sceR genes are fused, SceQ and SceR will be expressed as a single protein to prevent the insertion of any potential trans-PKS module. Production of sceliphrolactam is expected to be abolished for the fusion mutant because the trans-PKS module can no longer dock between the closely linked SceQ and SceR. Similar gene fusion experiment has been used to support an iterative mechanism in the biosynthesis of borrelin 36 . To create the sceQ-R fusion mutant, a pCRISPR-cas9 plasmid that harbors two sgRNA cassettes was constructed to target the sceQ/sceR intergenic region for the deletion of 14 base pairs (Fig. 5A) . Deletion of the 14 base pairs was expected to remove the stop and start codons and lead to the fusion of sceQ and sceR genes. The sgRNA and homology template-containing pCRISPR-cas9 plasmid was transformed into Streptomyces sp. SD85 strain using the same E. coli -Streptomyces conjugation method as the gene inactivation experiment described earlier. Deletion of the 14 base pairs was confirmed by gene sequencing for the four colonies we tested (Fig. 5B) . After cultivating the sceQ-R fusion mutant strains inoculated using four positive colonies, we found that sceliphrolactam was still produced by all four mutant strains, despite at a lower yield than the wild type strain (Fig. 5C) . The results suggest that the polyketide intermediate is passed from SceQ directly to SceR, and thus, it is tenuous to argue that a trans-PKS module is involved in the biosynthesis of sceliphrolactam.
A potential biosynthetic mechanism that involves an iterative PKS module. As the experimental evidence argue against the involvement of a trans-PKS module, the apparent lack of a PKS module in the biosynthesis of sceliphrolactam remains to be fully explained. One of the conceivable mechanisms involves the iterative use of a PKS module. The iterative use of modules in PKS systems is increasingly known as a common phenomenon and has been reported in the biosynthesis of lankacidin 37 , borrelidin 38 , aureothin 39 , stigmatellin 40 and other polyketide secondary metabolites 41 . There are two possibilities, with either SceQ or SceR acting iteratively (Fig. 4C,D) . If SceQ acts iteratively, the β-keto group is reduced in the first chain-extension cycle to generate a hydroxyl group that is subsequently dehydrated, but remains unreduced in the second cycle. On the other hand, if SceR acts iteratively, the β-keto group is not reduced in the first chain-extension cycle; but reduced to yield hydroxyl group in the second cycle. Regardless of which module acts iteratively, the iterative module seems to be "programmed" with the activity of the KR domain switching on and off in two successive extension cycles. Hence, in comparison with most known iterative mechanisms that involve modules acting iteratively with the processing domains (e.g. KR, DH, ER or MT) generating the same chemical outcome in each extension cycle, the putative iterative module in sceliphrolactam biosynthesis is able to generate different outcome during the two successive extension cycles. Such "programmed iteration" is rare but not unprecedented. It was recently found that the biosynthesis of azalomycin involves a similar iterative module. This iterative module contains an ER domain whose activity can be "toggled" off and on to ensure that the ER domain only functions in the second extension cycle 31, 42 . The selective keto-reduction on different polyketide intermediates by the SceQ or SceR module is also reminiscent of the programmed keto-reduction mechanism observed in partially reducing iterative PKSs 32, [43] [44] [45] . In summary, we have isolated and characterized a biosynthetically talented Streptomyces strain that harbors a large number of uncharacterized biosynthetic gene clusters. As an effort to explore the biosynthetic potential of the strain, we identified all the modular PKS-based BGCs and their products. For the polyene macrolactam sceliphrolactam, identification of the sce BGC suggests a potentially unique modular PKS system for macrolactam biosynthesis. Our experimental data suggest that the biosynthesis of sceliphrolactam potentially involves a "programmed" iterative PKS module. Among all the known polyene macrolactams, sceliphrolactam is the only one that features a biosynthetic mechanism that does not seem to follow the co-linearity rule by involving an iterative PKS module. Future mechanistic studies are required to identify which module acts iteratively and understand how the iterative domain achieves the programmed keto-reduction.
Experimental Procedures
Streptomyces sp. SD85 isolation and maintenance. Streptomyces sp. SD85 was isolated from marine sediment samples collected from the Sungei Buloh Wetland Reserve, Singapore. The sediment samples were collected from the sediment (1-2 meter depth) in the mangrove swamps to harvest the microbial communities from the submerged sediment. The sediment samples were rinsed and filtered after being air dried and treated with microwave irradiation. With the filtrate, a series of 10-fold dilutions were performed and a total of 0.1 mL from each dilution was plated onto the International Streptomyces Project (ISP3) medium plate. 30 μg/mL Cycloheximide and 25 μg/mL nalidixic acid were used to inhibit fungal and fast growing Gram-negative bacteria. All culture plates were incubated for up to three weeks. Individual colonies were obtained after a few rounds of streaking and the strain was maintained in GYM medium agar (4 g/L glucose, 4 g/L yeast extract, 10 g/L malt extract, 20 g/L agar, pH 7.2) at 28 °C.
Complete genome sequencing. High quality genomic DNA was extracted using a modified genomic DNA extraction protocol for Streptomyces 46 . The genomic DNA was first sequenced using illumine technology to obtain a draft genome which contains large gaps. Then the complete genome sequence of Streptomyces sp. SD85 was obtained using Single Molecule Real Time (SMRT) sequencing technology (Pacific Biosciences, California, USA). We sequenced the genome on a PacBio RS II platform. 1 SMRT cell was used and the sequencing run was performed 3 times. The PacBio long sequencing reads have reached an approximate 114 X coverage of the genome, and were successfully assembled into a linear chromosome with a size of 8,625,764 bp by using the Hierarchical Genome Assembly Process 2 (HGAP2) protocol from SMRT Analysis version 2. the PacBio technology, a single SMRT cell was used with a three sequencing runs. A read quality value of 84 was achieved with 86,939 zero-mode-waveguides (ZMWs), with average coverage value of 114.0. Mean polymerase read length was 15,610 bp with mean reads of inserts (ROI) readlength value of 13,164 bp. A single contig of length 8,625,764 bases was obtained after assembly.
Profiling of secondary metabolites in the culture broth and mycelia of Streptomyces sp. SD85.
Streptomyces sp. 85 was cultured in GYM liquid medium (100 mL in 500 mL baffled Erlenmeyer flask) for 96 hr at 28 °C. Mycelia were separated from culture broth by centrifugation. Mycelia and culture broth were extracted separately with methanol and ethyl acetate, respectively. The organic layers were dried under vacuum and re-dissolved in methanol. HPLC analysis of the crude extract was performed with Grace ® VisionHT TM C18-HL (4.6 mm × 250 mm, 5 µm) using an Agilent 1200 HPLC system equipped with DAD detector. A 60 min gradient elution at 1 mL/min was employed with 10% aqueous acetonitrile to 100% acetonitrile. Mobile phase solvents were supplemented with 0.1% formic acid. Analytes were monitored at λ = 220 nm, 280 nm, 330 nm, 400 nm. LC-MS was performed using Thermo Scientific Accela LC system coupled with an LTQ XL TM Linear Ion Trap Mass Spectrometer. The conditions for LC were similar to those employed for HPLC-DAD analysis. Mass spectra were measured using positive and negative ion mode of ESI (capillary voltage 3.5 kV; cone voltages 30 V/50 V; source temperature 400 °C; cone gas flow 60 L/hr; desolvation gas flow 450 L/hr) with a mass range of 100-2000 Da and a scan time of 0.5 s.
Large-scale fermentation and isolation of sceliphrolactam. Streptomyces sp. SD85 was cultured in GYM liquid medium (800 mL in 2 L baffled Erlenmeyer flask) for 7 days at 29 °C, in the dark. Combined mycelia from four culture flasks were extracted with one liter of acetone twice. The organic layer was dried under vacuum to afford a crude extract (~4 g). The extract was re-dissolved in 90% methanol and partitioned four times with equal volume of hexane to remove unwanted lipid material. The washed extract was subjected to semi-preparative reversed phase HPLC using Shimadzu Prominence Preparative HPLC system equipped with Zorbax Eclipse XDB C18 semi-prep column (9.4 mm × 250 mm, 5 µm). An isocratic solvent system of H 2 O:CH 3 OH (45:55) with a flow rate of 4.7 mL/min was used for compound isolation. Elution of the compounds was monitored at 333 nm and a peak corresponding to sceliphrolactam was observed at t = 22 min. Pure sceliphrolactam (2 mg/L) was obtained under dark conditions to minimize degradation of the polyene compound.
Construction of Streptomyces sp. SD85 ∆sceN mutants using CRISPR/Cas9 method. Construction of the plasmid pCRISPR-Cas9-SceN for CRISPR/Cas9-mediated sceN gene mutation in Streptomyces sp. SD85 was performed using pCRISPR-Cas9, which was a kind gift from Sang Yup Lee's lab in the Korea Advanced Institute of Science and Technology (KAIST). All cloning steps were carried out using E. coli TOP10 (Invitrogen, US). Identification of protospacer sequences in sceN was performed using the Benchling Server. Selected sceN DNA spacer was introduced into pCRISPR-Cas9 by ligating a PCR-generated sgRNA sequence into SnaBI and NcoI linearized pCRISPR-Cas9 vector. To generate an 883 bp deletion via homology directed repair, two DNA templates that are homologous to the 5′-and 3′-regions of the sceN gene and are 883 bp apart from each other were amplified from genomic DNA using Phusion ® high fidelity DNA polymerase. The sceN spacer-containing pCRISPR-Cas9 was digested using StuI restriction enzyme and jointed with the template DNA fragments using Gibson Assembly kit (New England BioLabs, US). The sgRNA and template-containing pCRISPR-Cas9 plasmid was introduced into the Streptomyces sp. SD85 parental strain by conjugation method using E. coli ET12567/ pUZ8002 as described 47 . Briefly, Streptomyces spores were collected from seven-day old culture grown on GYM agar containing 10 mM MgCl 2 and 10 mM CaCl 2 , and subjected to heat shock at 45 °C for 5 min. They were allowed to germinate at 30 °C for 6 hr and mixed with an exponential phase culture of E. coli ET12567/pUZ8002 containing the modified pCRISPR-Cas9 plasmid at a donor to recipient ratio of 3:1. The resultant mixture was plated onto MS agar supplemented with 40 mM MgCl 2 and 20 mM CaCl 2 , and incubated for 22.5 hr at 30 °C. One millilitre of sterile water containing 1 mg of apramycin and 500 µg of nalidixic acid was overlaid onto the plates for selection of successful exconjugants. Plates were further incubated at 30 °C for 4-5 days before exconjugants were picked onto fresh MS agar plates containing 40 μg/mL apramycin and 25 µg/mL nalidixic acid.
Exconjugants harbouring the modified pCRISPR-Cas9 plasmid were determined by colony PCR. True exconjugants were patched onto MS agar that contain 40 μg/mL apramycin and 10 μg/mL thiostrepton for induction of Cas9 expression. Clearance of plasmids was achieved by patching resultant colonies onto MS agar and incubating them at 37 °C for 4 days. Apramycin sensitivity was confirmed by replica plating onto selective and non-selective plates.
To screen for successful mutants, individual clones were cultured in liquid GYM at 30 °C for 3 days for genomic DNA isolation using a previously described protocol 48 . Diagnostic PCR was performed to establish a deletion of 883 bp in the sceN gene.
CRISPR/Cas9 mediated sceQ-R gene fusion. A dual sgRNA-containing pCRISPR-Cas9 plasmid was constructed by designing a dual sgRNA synthetic construct with a configuration of (NcoI site -spacer -sgRNA1tracr -terminator -gapdhp (EL) -spacer -sgRNAtracr -SnaBI site). This construct was cloned into SnaBI and NcoI linearized pCRISPR-Cas9 vector by Gibson Assembly. The resulted plasmid was linearized using the StuI restriction enzyme and ligated with the HDR template to yield the plasmid pCRISPR-cas9-dual-sceQR. Introduction of this plasmid into Streptomyces sp. SD85 and subsequent induction of Cas9 expression was performed as described above. Successful mutant strains were validated by diagnostic PCR and sequencing of the fragments amplified from genomic DNA of individual clones. HPLC analysis of sceliphrolactam production for the Streptomyces sp. SD85 ∆sceN and sceQ-R fusion mutants. The mycelia of 7 days old wild-type (WT) Streptomyces sp. SD85 and the mutant strains were extracted twice with equal volume of acetone and dried under vacuum. The crude extracts were re-dissolved in methanol and subjected to HPLC analysis with an Agilent 1200 HPLC system equipped with DAD for UV detection. A Gradient elution program was employed, starting with 40% aqueous methanol at 0 min to 70% aqueous methanol at 50 min and 100% methanol at 60 min. The analytes were monitored at λ = 220 nm, 280 nm, 330 nm, 420 nm. Experiments were repeated twice to ensure reproducibility.
Accession code. The BGC gene sequence has been deposited in public database (GenBank accession number: KX230849).
